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Abstract
Differential expression of proteins between tissues underlies organ-specific functions. Under certain pathological conditions,
this may also lead to tissue vulnerability. Furthermore, post-translational modifications exist between different cell types
and pathological conditions. We employed SILAM (Stable Isotope Labeling in Mammals) combined with mass spectrometry
to quantify the proteome between mammalian tissues. Using
15N labeled rat tissue, we quantified 3742 phosphorylated
peptides in nuclear extracts from liver and brain tissue. Analysis of the phosphorylation sites revealed tissue specific kinase
motifs. Although these tissues are quite different in their composition and function, more than 500 protein identifications
were common to both tissues. Specifically, we identified an up-regulation in the brain of the phosphoprotein, ZFHX1B, in
which a genetic deletion causes the neurological disorder Mowat–Wilson syndrome. Finally, pathway analysis revealed
distinct nuclear pathways enriched in each tissue. Our findings provide a valuable resource as a starting point for further
understanding of tissue specific gene regulation and demonstrate SILAM as a useful strategy for the differential proteomic
analysis of mammalian tissues.
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Introduction
A puzzling phenomenon in many neurological diseases is that
mutations in individual genes cause neurological specific pheno-
types, but the genes are ubiquitously expressed throughout the
body. It has been proposed that post-translational modifications
specific to one tissue may generate tissue specific functions for a
given protein. This has been demonstrated for methyl-CpG-
binding protein 2 (MECP2). MECP2 is a transcriptional repressor
through binding to methylated DNA, and mutations in this
protein cause the majority of the cases of Rett syndrome(RTT)
[1,2,3]. RTT is an X-linked neurodevelopmental disorder and is a
leading cause of mental retardation in females [4]. Although
MECP2 is ubiquitously expressed, it has been demonstrated that it
is phosphorylated at S421 only in the brain, and this neuronal
specific phosphorylation event leads to the transcription of brain-
derived neurotrophic factor (BDNF) [5], which is crucial for
neuronal cell development and neural circuits formation. Al-
though this MECP2 study is a breakthrough in the role of
phosphorylation in neurological disease, it is tempting to speculate
that other phosphorylation events might happen in MECP2 as
well as other master regulatory proteins during cell differentiation
and tissue development that contribute to pleiotropic functions.
However, there has been no quantitative large-scale analysis of the
phosphorylation differences between the brain and other mam-
malian tissues.
Protein phosphorylation has been studied extensively on an
individual basis, but there is an emerging trend to study
phosphorylation on a proteomic scale. Global analysis of protein
phosphorylation using tandem mass spectrometry (MS/MS) is
beneficial in several aspects. First, since MS/MS combined with
database searching algorithms directly derives sequence informa-
tion of peptides, it is therefore capable of identifying novel
phosphorylation sites [6,7,8]. Second, bioinformatic analysis of a
large number of phosphopeptides can help extract consensus
sequences indicating the kinase responsible for the phosphoryla-
tion [9,10,11]. Finally, mass spectrometry data is quantitative so
differences in the relative expression of phosphorylation events
between samples can be calculated.
Quantification can be achieved by comparing a peptide with an
identical peptide that is labeled with heavy isotopes (e.g.
13Co r
15N) [12,13]. Given that a mass spectrometer can recognize the
mass difference between light and heavy peptides, an abundance
ratio between the labeled and unlabeled peptides can then be
calculated from the respective ion chromatograms [14,15]. To
label a protein sample with stable isotopes, either metabolic or in
vitro labeling can be employed [16,17]. Alterations in protein
expression induced by a stimulus can be determined by analyzing
two samples utilizing the same labeled internal standard [14].
Metabolic labeling has advantages over in vitro labeling
techniques since it exploits the cell’s translational machinery to
label all the proteins, while some in vitro labeling techniques use
chemical reactions to label proteins with only certain functional
groups[18]. In addition, in vitro labeling techniques label peptides
after digestion, and then the light and heavy samples are mixed,
while metabolic labeling allows for the mixture of light and heavy
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specific organelle. Thus, metabolic labeling reduces the systematic
errors that may accumulate during sample preparation between
the heavy and light samples [14]. Metabolic labeling is routinely
used in simple systems, such as yeast and cultured mammalian
cells and has even been applied to simple organisms, including C.
elegans and D. melanogaster, to quantify hundreds to thousands of
unmodified and phosphorylated peptides [19,20]. In comparison,
few studies have performed large-scale quantitative phosphoryla-
tion analysis on mammalian tissue, and those that have employed
in vitro labeling techniques [21,22]. In order to study animal
models of disease, we developed the strategy SILAM (Stable
Isotope Labeling of Mammals) to metabolically label an entire
mammal for quantitative MS analysis [23,24]. This strategy
combines the necessity of studying mammalian tissues with the
quantitative advantage of metabolic labeling. We previously
demonstrated that labeling a rat with
15N for two generations
had no adverse health effects and generated an entire animal
highly enriched with
15N that was phenotypically normal [24]. We
validated the SILAM strategy by quantifying alterations in
unmodified peptides in liver tissue induced by a systemic injection
of cyclohexamide and in brain tissue during postnatal develop-
ment [23,25].
We propose that SILAM can be employed to quantitatively
compare the proteomes of different tissues. To validate our
strategy, we quantified differences between the liver and the brain
proteomes. The liver plays a major role in metabolism and has a
number of other functions in the body, including glycogen storage,
decomposition of red blood cells, and detoxification. The major
cells that carry out these functions are hepatocytes. In addition, the
liver is capable of regeneration. In contrast, the brain is incapable
of regeneration and controls movement, perception, and cognition
to generate complex behaviors. The brain consists of terminally
differentiated neurons and smaller dividing glia. We chose to
examine the nuclear proteome of these tissues, because although
the fundamental functions of the nucleus are similar in all cells,
nuclear proteins produce a variety of specific cellular character-
istics through differential control of gene expression.
Materials and Methods
Nuclear enriched sample preparation
Sprague-Dawley rats were labeled with
15N as previously
described [23,24]. Briefly, a female rat was fed a
15N labeled
protein diet starting after weaning, remaining on the
15N protein
diet throughout its pregnancy, and while feeding its pups. On
postnatal day 45 (p45), the pups were subjected to halothane by
inhalation until unresponsive, and the tissues were quickly
removed, frozen with liquid nitrogen, and stored at –80uC. The
15N enrichment was determined to be 96% using a previously
described protocol[26]. Livers and brains from unlabeled Sprague-
Dawley rats at p45 were obtained and stored in an identical
manner as the
15N labeled brains. All methods involving animals
were approved by the Institutional Animal Research Committee
(approval #07-0083) and accredited by the American Association
for Accreditation of Laboratory Animal Care.
Three snap-frozen p45 rat livers and brains, as well as
15N
enriched rat liver were homogenized in a buffer (1 g of tissue/
10 ml of buffer) containing 4 mM HEPES, 0.32 M sucrose,
protease and phosphatase inhibitors(Roche, Indianapolis, IN) in a
Teflon hand held dounce grinder. Before homogenization, the rat
livers were minced with a razor blade and then further grounded
with an Omni Tissue Master 125 electric grinder. After
determining the protein concentration with a BCA protein assay
(Pierce, Rockford, IL), homogenates from either liver or brain
were mixed at a 1:1(wt/wt) ratio with the
15N liver homogenate.
The nuclei were isolated following a previous published protocol
[27]. Briefly, the
14N/
15N mixture was added to 10 ml of buffer
and then was centrifuged at 8006g for 15 minutes. The resulting
pellets were resuspended in 1 ml of buffer containing 0.5% NP-40,
and then, incubated on ice for 2 hours. The lysate was added to
10 ml of buffer and centrifuged at 8006 g for 15 minutes. The
resulting pellets were homogenized in 500 ul of buffer and protein
concentration was determined with a BCA protein assay. In total,
this resulted in three
14N liver/
15N liver nuclear preparations and
three
14N brain/
15N liver. Verification of the purity of this nuclear
preparation by western blot analysis has been previously published
[28].
Trypsin digestion and enrichment of phosphopeptides
using Immobilized Metal Affinity Chromatography
(IMAC)
One milligram of each
14N/
15N mixture was precipitated with
trichloroacetic acid at a final concentration of 20% for 30 minutes
and washed twice with cold acetone. The pellets were then
solublized by sonication with 100 ul 5x Invitrosol (Inivtrogen,
Carlsbad, CA) with 4M urea, reduced with 10 mM dithiothreitol
and alkylated with 10 mM iodoacetamide for 30 minutes at room
temperature, respectively. The solutions were diluted with 4x
volumes of 100 mM Tris-HCl(pH 8.0), and then digested with
trypsin (1:100 enzyme/substrate) overnight at 37uC. After
digestion, the enzymatic reaction was terminated using 5% acetic
acid.
The enrichment of phosphopeptides was performed using a
gallium-based IMAC column (Pierce, Rockford, IL), according to
manufacturer’s protocols with minor modification. Briefly, about
100 mg of protein digest in 5% of acetic acid was loaded onto each
IMAC column. After two washes with 0.1% acetic acid and two
washes with 0.1% acetic acid plus 10% acetonitrile, the bound
peptides were eluted four times with 20 ml of 100 mM ammonium
bicarbonate, pH 9. The resulting eluate was acidified with 5%
formic acid before mass spectrometry analysis.
Analysis of phosphopeptides by Multi-Dimensional
Protein Identification Technology (MudPIT) and Linear
Ion Trap-Orbitrap
The eluted peptides from each IMAC column were analyzed by
one MudPIT experiment for a total of six MudPIT experiments.
The MudPIT experiment was based on a previous method [29]
with modifications tailored to phosphopeptide analysis. Peptides
were pressure-loaded onto a 250-mm i.d. fused silica capillary
column packed with a 2.5 cm long, 5 mm Partisphere strong cation
exchanger (SCX, Whatman, Clifton, NJ) and a 2.5 cm, 10 mm
Jupiter resin (Phenomenex, Ventura, CA), with the SCX end
fritted with immobilized Kasil 1624 (PQ Corperation, Valley
forge, PA). After desalting, a 100-mm i.d. capillary with a 5-mm
pulled tip packed with 15 cm 4-mm Jupiter C18 material was
attached to the SCX end with a ZDV union, and the entire
column was placed inline with an Eksigent pump (Eksigent
Technologies, Dublin, CA). Three buffer solutions used were: 5%
acetonitrile/0.1% formic acid (buffer A); 80% acetonitrile/0.1%
formic acid (buffer B), and 500 mM ammonium acetate/5%
acetonitrile/0.1% formic acid (buffer C). Each analysis consisted of
four chromatography steps. The first step consisted of a 100 min
gradient from 0–100% buffer B. Steps 2–4 had the following
profile: 3 min of 100% buffer A, 5 min of X% buffer C, a 10 min
gradient from 0–15% buffer B, and a 130 min gradient from 15–
Quantitative Tissue Proteomics
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e1603945% buffer B, followed by a 20 min gradient increase to 100%
buffer B, and a reverse of gradient to 100% buffer A. The 5 min
buffer C percentages (X) were 30, 70% and 100% respectively. As
peptides were eluted from the microcapillary column they were
electrosprayed directly into a hybrid LTQ linear ion trap and
Orbitrap (ThermoFisher, San Jose, CA) with the application of a
distal 2.4 kV spray voltage. A cycle of one full-scan with 60,000
resolution at 400 m/z by Orbitrap (400-1400 m/z) followed by five
data-dependent MS
2 scan plus neutral loss-dependent MS
3 scan
by LTQ was repeated continuously throughout each step of the
multidimensional separation. A precursor ion neutral loss of 98, 49
or 32 Daltons in the MS
2 spectra was selected for further
fragmentation. Normalized collision energy of 35% was used while
acquiring the MS
2 and MS
3 spectra. The following dynamic
exclusion parameters were used: repeat count -1, repeat duration –
30, list size – 100, exclusion duration – 80.
Identification, quantification of phosphopeptides and
phosphoproteins; bioinformatic analysis
MS
2 and MS
3 spectra were analyzed using the following
software analysis protocol. Both spectra were searched with the
ProLucid algorithm[30] against the rat IPI database (ftp://ftp.ebi.
ac.uk/pub/databases/IPI/, version 3.17, releasing date May 18,
2006), that was concatenated to a decoy database in which the
sequence for each entry in the original database was reversed. The
search parameters include a static cysteine modification of
57.02146 amu and differential modification on serine, threonine
and tyrosine residues of 79.9663 amu. Trypsin specificity was
required for all peptides. The database search results were
assembled and filtered using the DTASelect program with a
spectra level false discovery rate of less than 0.5%, mass accuracy
of 5 ppm. Under such filtering conditions, the estimated false
discovery rate was below 1% at the peptide level.
The assembled search result file was used to obtain quantitative
ratios between
14N (sample) and
15N (reference) using the software
Census [31]. Census allows users to filter peptide ratio measure-
ments based on a correlation threshold because the correlation
coefficient (values between zero and one) represents the quality of
the correlation between the unlabeled and labeled chromatograms
and can be used to filter out poor quality measurements. In this
study, only peptide ratios with correlation values greater than 0.5
were used for further analysis. For singleton analysis, we required
the
14N/
15N ratio to be greater than 5.0 and the threshold score to
be greater than 0.5. The threshold score ranges from zero to one
and represents the quality of the singleton analysis with one being
the most stringent.
For Gene Ontology (GO) analysis, annotations were obtained
from www.geneontology.org. Almost all nuclear proteins were
annotated with multiple molecular functions. For the construction
of the pie graph, the first molecular function was chosen.
For Motif analysis, we used Motif-X v1.2 (http://motif-x.med.
harvard.edu/motif-x.html) [9]. We used the default settings, which
include a total number of 13 characters in the motif, at least 20
occurrences of the motif in the sample input, and a p-value of
0.000001 for the selection of significant residue/position pairs in
the motif. The rat IPI database was used for background analysis.
Ingenuity software was employed for global analysis [32]. The
input was phosphoproteins that were 1.5 fold higher in either
tissue as analyzed with Census plus phosphoproteins that were
identified by at least 3 peptides in one tissue and not identified in
the other tissue. The following parameters where used for the
analysis. The reference set was genes from the Ingenuity
Knowledge Base including all species, tissues, and cell lines.
Analysis consisted of direct and indirect relationships including
protein-protein interactions, microRNA-mRNA interactions, or
Ingenuity Expert findings. Right-tailed Fisher’s exact test was used
to calculate a p-value determining the probability that each
biological function and/or disease assigned to that data set is due
to chance alone.
Results and Discussion
High confidence identification of phosphopeptides from
tissue nuclear extraction
Homogenates from either liver or brain (designated
14N liver
and
14N brain) of rats were mixed at a 1:1(wt/wt) ratio with a liver
homogenate from a rat labeled with
15N enriched diet (designated
15N liver). After a nuclear extraction, the samples were digested
with trypsin, and the resulting peptides were applied to
immobilized metal ion affinity chromatography (IMAC) column
to enrich for phosphopeptides. The phosphopeptide enriched
fraction was analyzed by multi-dimensional protein identification
technology (MudPIT) with neutral loss dependent MS
3 using a
LTQ-Orbitrap hybrid mass spectrometer. The resulting spectra
were searched with a decoy database with a final peptide false
discovery rate less than 1%. We identified a total of 4028 (3433
unique) phosphorylated peptides comprising 1014 proteins from
the brain analysis, and 3108 (2188 unique) phosphorylated
peptides comprising 849 proteins in the liver analysis (Figure 1).
For this dataset, 439 phosphoproteins and 654 unique phospho-
peptides were identified in both the
14N brain and
14N liver. For
unmodified proteins, we identified 471 proteins from 2123 (1680
unique) peptides in the brain, and 670 proteins from 3130 (2066
unique) peptides in the liver (Figure 1). For this dataset, 192
unmodified proteins were identified in both the
14N brain and
14N
liver. Thus, IMAC was able to enrich phosphopeptides from
complex tissues, and ample similarities between the protein
identifications were observed to proceed with the quantification
of the differences between these tissues.
Due to altered fragmentation patterns, phosphopeptides can
result in less confident identifications compared to unmodified
peptides. We employed a data dependent MS
3 strategy to increase
the confidence of our phosphopeptides identifications. In this
strategy, a precursor ion neutral loss in the MS
2 spectra is selected
for further fragmentation, and the fragmentation pattern appears
in the MS
3 spectra. The neutral loss ions are formed by loss of
phosphoric acid and are often very prominent in MS
2 spectra.
Thus, the data dependent MS
3 is applied in phosphopeptide
analysis to increase the confidence of identifications [8]. We
identified 1361 phosphorylated peptides from MS
3 spectra in the
brain analysis, which confirmed 683 phosphorylated peptides from
the MS
2 identifications (Table 1). We identified 1246 phosphor-
ylated peptides from MS
3 spectra in the liver analysis, which
confirmed 557 phosphorylated peptides from the MS
2 identifica-
tions (Table 1). Since only a neutral loss from a phosphorylated
peptide can trigger a MS
3 event, we considered these identifica-
tions to be highly confident, and we increased the number of
phosphopeptide identifications employing this MS
3 strategy. In
theory, every phosphopeptide identified in a MS
2 spectrum should
generate a higher quality MS
3 spectrum, but in application, this is
not the case for many reasons. It is most likely that the number of
fragment ions in the MS
3 scan is not large enough to identify a
phosphopeptide due to the insufficient trapping of the neutral loss
peptide ions. Alternatively, a MS
3 event may not be triggered
when a phosphopeptide analyzed by an MS
2 scan does not
undergo complete neutral loss of phosphate [22], or proline-
directed fragmentation in MS
2 generates ions that are more
abundant than the neutral loss peptide ions. In our analysis, MS
3
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2 spectra, and similar
numbers have been reported by other laboratories [8,33].
We also applied an in-house machine-learning computer
program, Debunker [34], to validate phosphopeptide identifica-
tions derived from MS
2 spectra. The advantage of the Debunker
algorithm over the MS
3 strategy is that it is capable of analyzing all
MS
2 spectra for features distinctive of phosphopeptides. Prominent
spectral features, such as neutral loss of precursor ions, neutral loss
of fragment ions, and intensity of b or y ion series, are
incorporated to calculate a probability score using a support
vector machine binary classification to predict the validity of the
phosphopeptide identification. The predictive value from 0 to 1 is
assigned to the possible phosphorylation event. A value less than
0.5 means the phosphorylation prediction is negative, while a
value greater than 0.5 means the prediction is positive for a
phosphorylation event. A value closer to 1 indicates the
phosphorylation event is more likely to be true. Requiring a
predictive value greater than 0.95, 73% of the phosphopeptides
from the brain analysis and 86% of the phosphopeptides from the
liver analysis were determined as a highly confident phosphopep-
tide (Table 1). Thus, Debunker is superior for phosphopeptide
validation than the MS
3 strategy, but the MS
3 spectra did result in
additional phosphopeptides that were not identified from the MS
2
spectra. Finally, neither method is capable of validating phospho-
tyrosine peptides, which accounted for less than 5% of our
phosphopeptides identifications (data not shown).
Kinase Motif Analysis
We examined the phosphorylation site localization of the
peptides that were validated by Debunker. To determine the exact
amino acid that is phosphorylated can be difficult with mass
spectrometry data unless only one possible phosphorylation site
exists in the peptide [35]. To determine the site localization of
peptides containing multiple possible phosphorylation sites, we
employed a binomial probability approach that has previously
been reported [35,36]. We confidently localized the phosphory-
lation site in 578 and 431 unique phosphopeptides in the
14N
brain and
14N liver, respectively. The most obvious characteristic
of these phosphopeptides is that the majority (.75%) of these
phosphorylated amino acids were followed by either proline, or an
acidic residue (glutamate, or aspartate) (Figure 2A). The
percentage of phosphorylation sites followed by a proline was
greater in the brain, and the percentage of phosphorylation sites
followed by an acidic residue was greater in the liver. To further
examine these phosphopeptides, we employed the algorithm,
Motif-X, to identify kinase motifs within our data[9]. When
requiring a significant motif to be present at least twenty times in
either brain or liver, we identified 11 and 10 motifs in the brain
and liver, respectively (Table 2). Only two motifs were identified in
both tissues (Figure 2B). Motif-X also computes a fold increase of
the kinase motif in the sample by determining the total number of
motifs found in the entire rat database. For example, the motif,
PxxxKSPxxKx, occurred 27 times in the brain sample, while only
Figure 1. Peptide identifications from liver and brain tissue. The number (y-axis) of phosphorylated and unmodified proteins identified from
brain and liver on a LTQ-Orbitrap mass spectrometer following the phosphopeptide enrichment using IMAC.
doi:10.1371/journal.pone.0016039.g001
Table 1. Validation of phosphopeptides identified from MS
2 spectra with MS
3 spectra and Debunker.
MS
2 peptides MS
3 peptides MS
2=MS
3 Debunker validated peptides
Brain 4028 1361 683 2934
Liver 3108 1246 557 2695
doi:10.1371/journal.pone.0016039.t001
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a fold increase greater than 1200. Consistent with this calculation,
this motif was found in two annotated proteins, neurofilament M
(NF-M) and neurofilament H(NF-H), which are highly abundant
in brain tissue [37]. Furthermore, 12 out of the 19 observed
consensus sequences have been linked to known kinases. Using
different enrichment methods, a similar motif distribution was
demonstrated with the nuclear extract of HeLa cells and mouse
brain [8,38], but another study has demonstrated that the yeast
phosphoproteome contains more motifs with basic and other
residues [15]. The observation of abundant proline motifs in the
brain suggests that proline-directed kinases are more active or
abundant in this tissue compared to the liver. Since it has been
demonstrated that drug treatment can cause changes in percent-
ages of proline-directed and acidic phosphopeptide motifs
identified by mass spectrometry [39], the differences between
liver and brain may represent differential activation of signaling
systems. Consistent with the analysis of nuclear extract, the
majority of the motifs observed are recognized by casein II kinase
(CKII), which is mostly localized to the nucleus [40], and many
CKII motifs were also observed in the phosphorylation analysis of
HeLa nuclear extract indicating this nuclear kinase is very active
in liver, brain, and cervix(HeLa) [8]. This corresponds to a report
stating CKII has over 300 known substrates (nuclear and
cytoplasmic), and it has been proposed that this kinase accounts
for a significant portion of a cell’s phosphoproteome [41].
Although CKII motifs were abundant in both tissues, different
CKII motifs were observed in the brain and liver. This indicates
that CKII may be differentially regulated, which has been
previously proposed [42].
Quantification of liver and brain proteomes
The peptides were quantified with Census, which extracts the
14N and
15N chromatograms for each peptide and determines the
14N/
15N ratio using linear regression analysis [31] (Table S1). The
high confidence in our phosphopeptide identifications also
extended to our quantified phosphopeptides (Table 3). Greater
than 80% of quantified MS
2 peptides were validated by Debunker.
The quantification efficiency (the percentage of identified peptides
assigned a confident
14N/
15N ratio) was dramatically different
between the samples. In the liver, we observed 86.3% quantitation
efficiency, and in the brain, we observed 41.7% quantitation
efficiency for the phosphopeptides (Figure 3A). Since
15N liver was
used as the internal standard, many phosphopeptides that were
Figure 2. Tissue specific kinase motifs. A, The amino acid following the phosphorylated amino acid was categorized as proline, acidic, basic, or
other. The majority of these amino acids were either proline or acidic. The y-axis represents the percentage of phosphopeptides, where the
phosphorylation site could be confidently localized. B, The Motif-X algorithm was employed to determine if any kinase motifs existed in the data. The
percentage of peptides that contained a proline, acidic, or basic residue in their motif was plotted. For peptides which contained two of these
residues, they were counted in both categories. The majority of motifs contained either a proline or acidic residue.
doi:10.1371/journal.pone.0016039.g002
Table 2. Differential phosphorylation motifs identified in the
liver and brain.
Motif Peptides
Fold
Increase Tissue Kinase Hela
xxxxxxSxxxxxE 20 4.2 Brain Unknown No
xxxxxxSxDxxxx 27 5.1 Brain CAMKII Yes
xxxxxxSxExxxx 35 4.6 Brain CKII Yes
xxxxxxSDxExEx 20 128.5 Brain CKII Yes
xxxxxxSDExxxx 21 32.8 Brain Unknown No
xxxxxxSExExxx 33 21.6 Brain CKII Yes
xxxxxxSPxxExx 30 17.2 Brain Unknown No
xPxxxKSPxxxKx 27 11255 Brain Unknown No
xxxxxxTPxxxxx 21 6.8 Brain Unknown Yes
xxxxxxSxxExxx 49(B), 40(L) 4.2 Brain,
Liver
CKII Yes
xxxxxxSPxxxxx 149(B), 98(L) 5.3 Brain,
Liver
ERK1, ERK2, GSK-3 Yes
xxxxxxSxxDxxx 21 4.8 Liver CKII Yes
xxxxxxSxxEExx 20 16.1 Liver Unknown No
xxxxxxSDxExxx 29 24.1 Liver CKII Yes
xxxxxxSDEExxx 24 117.7 Liver CKII Yes
xxxxxxSEEExxx 21 58.9 Liver CKII Yes
xxxxxDSDxxxxx 21 41.8 Liver CKII-like Yes
xxxRxxSxxxxxx 31 4.5 Liver CAMKII, PKA, PKC Yes
xxxRxxSPxxxxx 25 15.2 Liver Unknown Yes
The motifs were linked to the following kinases: Ca 2+/Calmodulin-Dependent
Protein Kinase II (CAMKII) [35], Casein kinase II (CKII) [35], Cyclin-Dependent
Kinase 5 (CDK5) [70], Extracellular Regulated Kinase 1 (ERK1) [70], Extracellular
Regulated Kinase 2 (ERK2) [70], Glycogen synthase kinase 3 (GSK-3) [70], Protein
Kinase A (PKA) [70], and Protein Kinase C (PKC)[ 70]. The last column denotes
motifs that were also observed in Hela nuclear extracts using Motif-X [35].
doi:10.1371/journal.pone.0016039.t002
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15N
phosphopeptide in the liver. The quantification efficiency for
unmodified peptides was 56.3% and 84.0% for the brain and liver,
respectively, suggesting it is indeed the choice of internal standard
and not restricted to the phosphopeptide analysis (Figure 3A). We
also observed a different distribution of
14N/
15N ratios for proteins
in the liver and brain analyses. The width of the protein
14N/
15N
distribution in the liver analysis was much smaller compared to the
brain analysis (Figure 3B). Thus, our choice of the internal
standard resulted in much larger differences quantified between
brain and
15N liver compared to liver and
15N liver as expected.
Singleton Analysis
The low quantification efficiency of the proteins from the brain
analysis suggests that a
15N liver peptide for the corresponding
14N
brain peptide was absent or below the limit of detection of the mass
spectrometer. To retrieve this data, we performed singleton analysis
on the peptides that did not pass the final filtering of Census. Census
quantifies all peptides and generates a quality score, ranging from 0
to 1, to reflect the linear regression analysis of the
14N and
15N
peptides. For our analysis, we required a peptide have a score
greater than 0.5 for a confident correlation between the
14Na n d
15N peptides and to consider a peptide quantified. Scores below 0.5
may be due to noisy uninterruptible data or the detection of only
one peptide and not the other (e.g. a heavy peptide is observed, but
not the light or vice versa), which is described as a singleton peptide.
To separate singleton peptides from noise, we required at least a 5
fold difference between the
14N and
15N peptides, and a composite
score of 0.95. The composite score ranges from 0 to 1 with 1
representing a highly confident singleton peptide. In addition, there
is a possibility that singleton peptides are misidentified peptides and
thus, there is no corresponding peptide to be found. To avoid this
possibility, we required a protein to possess at least three singleton
peptides. For phosphopeptides, we observed 202 unique peptides
(24 proteins) in the brain that were classified as singleton peptides,
and no singleton peptides were observed in the liver (Figure 4A and
Table S2). For unmodified peptides, we observed 128 unique
peptides (15 proteins) in the brain that were classified as singleton
peptides and 30 unique peptides (3 proteins) in the liver (Figure 4A).
Although it was unexpected to find singleton peptides in the liver
analysis, it may result from individual differences between animals.
To verify the unmodified singleton analysis was generating accurate
results, we compared ourunmodifiedsingleton proteins identifiedin
14N brain to the immunohistochemistry analysis of human tissues in
the Human Protein Atlas (HPR) (http://www.proteinatlas.org).
Ten out of these fifteen singleton proteins were documented in the
HPR, and all ten proteins were observed to have a greater
immunoreactivity in the brain compared to the liver (Table S2).
Seven proteins were documented as singleton proteins in both
phosphorylated and unmodified protein analysis suggesting that the
protein expression is dramatically different between liver and brain
regardless of the modification. For example, calmodulin Kinase II
alpha (CAMKII-alpha), has been reported to be highly expressed in
the brain [43] compared to other tissues. Twenty of these singleton
phosphoproteins were also quantified by Census with very large
average
14N/
15N ratios indicating these phosphoproteins may be at
the limit of detection (Table S2). For example, three singleton
phosphopeptides were observed for cyclic AMP-dependent tran-
scription factor (ATF-2), and an identical phosphopeptide was
assigned a
14N/
15N ratio of 42.5 (Figure 4B). Interestingly, a
different phosphopeptide from ATF-2 was a assigned a
14N/
15N
ratio of 3.7 (Figure 4B) indicating some phosphorylated sites on this
Table 3. Validation of quantified phosphopeptides with MS
3 spectra and Debunker.
MS
2 quantified MS
2 quantified = MS
3 MS
3 quantified MS
2 quantified validated by Debunker
Brain 1680 404 517 1416
Liver 2682 406 433 2326
doi:10.1371/journal.pone.0016039.t003
Figure 3. Quantification of the liver and brain proteomes. A, The number of phosphorylated and unmodified proteins identified and
quantified from brain and liver tissue. B, The distribution of the N
14/N
15 ratios for the phosphopeptides in brain and liver tissue.
doi:10.1371/journal.pone.0016039.g003
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others are quite different. ATF-2 is a basic region-leucine zipper
(bZIP) transcription factor and can activate transcription through
cAMP response elements as a homodimer or heterodimer with
members of the Jun/Fos family of transcription factors [44,45,46].
The ability to dimerize witha varietyof proteinsmay result insubtle
changes in DNA binding specificity [47,48]. ATF-2 mRNA has
beenreporttobe abundantinbraincompared tootheradult tissues,
but in liver, ATF-2 mRNA has been demonstrated to increase after
a partialhepatectomy [49]. This has led to the hypothesis that ATF-
2 regulates hepatocyte proliferation in the liver, but in the brain,
plays a wider role in the signal transduction of differentiated
neurons. The mechanism by which ATF-2 can support different
functions in specific cell types is unknown. One possibility is that
differential phosphorylation events can modulate the role it plays in
a cell by altering its affinity for DNA or binding partners, such as c-
Jun. Supporting this differential phosphorylation theory, it has been
demonstrated that certain phosphorylation events within ATF-2
occuruponserumstarvationwhileothersareunaffected[50,51].To
further complicate the regulation of ATF-2, it has been shown to be
phosphorylated by multiple kinases [52,53,54,55]. The novel
phosphorylation site we observed to be 40-fold greater in brain is
adjacent to its bZIP domain. Since this domain regulates its DNA
binding specificity, it is possible that this phosphorylation event
could alter the specific genes that are transcribed upon different
extracellular signals, which is consistent with other transcription
factors [56].
Nuclear Proteome
Out of the GO annotated quantified proteins, 45% and 48%
were annotated with a nuclear localization from brain and liver,
respectively, with a similar distribution of molecular nuclear
functions (Figure 5). This level of nuclear protein enrichment is
consistent with a previous report on the nuclear proteome of brain
tissue [57]. In total, there were 222 GO annotated phosphopro-
teins quantified in both liver and brain (Table S3). Out of these
nuclear proteins, twenty-one proteins were at least 1.5 fold
enriched in the brain nuclear proteome, while eighteen proteins
were at least 1.5 fold enriched in the liver nuclear proteome. The
nuclear phosphoprotein that was one of the most up regulated in
the brain was ZFHX1B, (Zinc finger homeobox 1B, also named
SIP1 and ZEB2). ZFHX1B was observed to be seven fold higher
in the brain. ZFHX1B is a DNA-binding transcriptional repressor
and activator [58,59]. Although this gene is expressed in all tissues,
ZFHX1B deletions cause Mowat–Wilson syndrome (MWS),
which is characterized by severe mental retardation and other
defects, including cardiac and urogential defects, but normal liver
function [60]. The molecular mechanisms are poorly understood,
but ZFHX1B has been demonstrated to be directly involved in
two phosphorylation signaling pathways: Transforming growth
factor beta receptor pathway [58] and the Wnt/JNK pathway
[61]. Thus, we quantified two novel phosphorylation sites in the
brain and liver, which may provide insight into the specific
phenotype of MWS. The nuclear phosphoprotein that was one of
the most up regulated in the liver was core histone macroH2A1,
which was observed to be more than fourfold increase in the liver.
Core histone proteins are a highly evolutionary conserved basic
structural unit of chromatin with roles in DNA packaging and
gene expression, however, it has been suggested that different cell
types possess unique combinations of these histone proteins
[62,63]. Consistent with this theory, it has been previously
reported that macroH2A1 is up regulated in rat liver compared
to rat brain [64].
Figure 4. Singleton analysis. A, Phosphorylated and unmodified peptides determined to be singleton peptides. B, Three singleton
phosphopeptides (green) were observed for ATF-2 with the sequence: AQS@EESRPQSLQQPATSTTETPASPAHTT@PQTQNTSGR. An identical
phosphopeptide, was also assigned a N
14/N
15 ratio of 42.5. A different phosphopeptide (red) of ATF-2, MPLDLS@PLATPIIR was quantified with a
N
14/N
15 ratio of 3.7 with Census.
doi:10.1371/journal.pone.0016039.g004
Figure 5. The nuclear proteome. The molecular functions annotated by GO of the quantified nuclear phosphoproteins from liver and brain.
doi:10.1371/journal.pone.0016039.g005
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To identify global differences between the phosphoproteomes, we
performed pathway analysis on the phosphoproteins up-regulated in
these proteomes using Ingenuity Pathways Analysis (IngenuityH
Systems, www.ingenuity.com). For this analysis, we included
quantified phosphoproteins with greater than 1.5 fold increase in
expression compared to the other tissue and phosphoproteins that
were identified by at least 3 peptides in one tissue, but not identified in
the other tissue (Table S5 and Table S6). For the brain
phosphoproteome, the largest cellular function represented was
cellular assembly and organization with 102 of the 211 proteins
analyzed designated with this function (Table S7). Many of these
proteins are regulators of the cytoskeleton, which have been
demonstrated to interact with the nucleus. For example, the APC
(adenomatous polyposis coli) protein directly binds to the nuclear
pore complex and the cytoskeleton [65]. NUMA (nuclear mitotic
apparatus protein) was also identified in the category, which is a
component of the nuclear matrix [66]. The nuclear matrix is a
network of structural proteins analogous to the cytoplasmic
cytoskeleton and hypothesized to maintain the nuclear structure
and the functional subcompartments: nucleoli, speckles, and PML
bodies [67]. Our data suggests that the nuclear matrix is more
abundant in the brain compared to the liver. Consistent with our
data, it has been reported neurons possess a more stable and larger
nuclear matrix than liver hepatocytes [68]. The most significant
pathway represented in our brain phosphoproteome was the PKA
(protein kinase A) signaling pathway with a p-value ,1.05610
29
(Table S8), which measures how likely the observed association
between a specific pathway and our dataset would be if it was only
due to random chance. The nuclear targets of the PKA pathway up-
regulated in the brainphosphoproteomewere beta-catenin, histone 1
cluster protein, and ATF-2. This pathway regulates many processes
in the brain, including memory and addiction [69]. For the liver
phosphoproteome, the largest cellular function represented was gene
expression with 61 out of the 119 phosphoproteins analyzed
consisting of proteins that regulate transcription (Table S9). The
most significant pathway (p-value ,2.16610
-5) represented was
farnesoid X receptor (FXR) and retinoid X receptor (RXR)
activation (Table S10). FXR is a nuclear receptor that is activated
by bile, whichisgenerated inthe liver. Along with RXR, FXR plays a
key role in bile regulation. Overall, this global analysis reveals that the
nuclear phosphoproteomes of liver and brain tissue are functionally
distinct to support the different functions of these tissues.
Conclusions
It has been proposed that differential phosphorylation between
tissues may alter the function of proteins. This hypothesis may
explain why many neurological diseases, such as Alzheimer’s
disease and Huntington’s disease, are caused by mutations in
ubiquitously expressed proteins, but the phenotypes are restricted
to the central nervous system. Support for this hypothesis comes
from a recent report demonstrating MECP2, which is mutated in
the neurological disorder Rett syndrome, is phosphorylated at
S421 in the brain and no other tissues tested [5]. Thus,
quantitative analysis of phosphoproteomes between tissues of
animal models of disease can extract novel and potential
therapeutic information. Our findings provide a valuable resource
as a starting point for further understanding of tissue specific gene
regulation. Overall, using SILAM, we demonstrated for the first
time the quantitative analysis of phosphoproteomes of different
mammalian tissues.
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